The bill seeks to extend the Accelerating Access to Critical Therapies for ALS Act until 2031, amending and enhancing the program for grants for research on therapies for ALS. This includes the review of clinical trial status and the clarification of the definition of participating clinical trials. It also requires the Commissioner of Food and Drugs to publish a report containing updated action plans for ALS and rare neurodegenerative diseases and mandates the submission of a report by the Comptroller General of the United States containing analyses and data on the program.